Telehealth News Network The consumer watchdog for getting care online
Getting Treatment Online

Getting peptides by telehealth: legit prescriptions vs. the gray market

Which peptides a clinic can actually prescribe, which are sold as 'research chemicals not for human use,' and the red flags that separate a real provider from a gray-market storefront.

Close-up of brown glass bottles on a shelf in a laboratory environment.

Peptides are everywhere online right now, sold with before-and-after photos and one-click checkout. But there is a hard line running through that market, and most buyers never see it. On one side are peptides a licensed clinician can lawfully prescribe. On the other are vials shipped with a label that reads “research chemical, not for human consumption.” This piece is about how to tell which side a given website is on, and what the law actually allows. For the underlying science on what these molecules do, see our sister publication Peptide News Network; here we stay on access and legitimacy.

The two-tier system, briefly

Some peptides are FDA-approved drugs with a brand name behind them. Others exist only as “bulk drug substances” that compounding pharmacies might mix to order. The FDA sorts nominated bulk substances into interim categories under Section 503A of the Food, Drug, and Cosmetic Act. For Category 1 substances, the agency generally does not intend to take action against compounding while it finishes its review. Category 2 is the list of substances for which the FDA has “identified significant safety risks,” and it does not intend to allow pharmacies to compound them.

That distinction matters, but for most popular peptides the more basic point is simpler: to be compounded lawfully under 503A, a bulk substance generally has to be on the 503A list, be the subject of a USP monograph, or be a component of an FDA-approved drug. A peptide that is none of those is not something a legitimate pharmacy can compound for you, no matter how professional the website looks.

The best-known “healing” and performance peptides sit in a regulatory gray zone rather than a green light. BPC-157 spent years on the Category 2 “do-not-compound” list before the FDA removed it — along with roughly a dozen other peptides, including TB-500 and KPV — in April 2026 after the parties who had nominated them withdrew the requests. Crucially, the FDA has said that removal from Category 2 does not make these substances eligible for compounding under 503A. None of them is FDA-approved, and the Department of Defense’s Operation Supplement Safety program flatly calls BPC-157 a prohibited peptide and an unapproved drug, noting there is no FDA-approved product and no legal basis to sell it as a dietary supplement.

The picture is still moving. The FDA’s Pharmacy Compounding Advisory Committee is scheduled to weigh several of these substances at its July 23-24, 2026 meeting, which lists BPC-157, TB-500, KPV, and MOTS-c among the bulk substances under consideration for the 503A list. Going in, the FDA’s own briefing has proposed that these peptides not be added. “Under review” is not the same as “approved,” and it is not the same as “safe to buy from a website today.”

The “research chemical” dodge

This is why so many sellers hide behind a disclaimer. A vial labeled “for research use only” or “not for human consumption” is being sold outside the drug system on purpose. The label is a liability shield, not an approval. Products sold this way are not tested to prescription standards for purity, sterility, dose accuracy, or contamination, and buying one means you are the quality-control department.

It is also worth knowing that this market is under active enforcement. In the parallel GLP-1 space, the FDA has clarified compounding policy as shortages resolved and, in March 2026, warned 30 telehealth companies over allegedly false or misleading marketing of compounded drugs. The regulators watching that space are the same ones watching peptides.

Red flags of a gray-market storefront

  • No prescription and no clinical evaluation. A legitimate provider assesses you first. “Add to cart, no doctor needed” is a research-chemical model.
  • “Research use only” or “not for human consumption” anywhere on the product or site.
  • No named pharmacy or prescriber. You should be able to learn which state-licensed pharmacy is filling the order. You can cross-check accredited digital pharmacies through the National Association of Boards of Pharmacy at safe.pharmacy.
  • Crypto-only or wire-only checkout, overseas shipping, and lyophilized “kits” with bacteriostatic water sold separately.
  • Claims of curing or treating disease. Unapproved drugs are not allowed to make those claims, and doing so invites the enforcement above.

What “legit” looks like

A defensible path runs through a real clinician who evaluates you, a prescription written for a specific person, and a state-licensed pharmacy that fills it. If the peptide you want is not something that can be lawfully compounded or dispensed, a legitimate provider will tell you so, rather than routing you to a “research” vendor. The absence of that friction is not convenience. It is usually the tell.

This article is journalism about access and legitimacy, not medical advice, and it makes no claim about whether any peptide is safe or effective. Those questions belong to your clinician and to the cited authorities.

Frequently asked questions

Can a telehealth doctor legally prescribe BPC-157?

Not as a compounded drug. BPC-157 is not FDA-approved and is not on the FDA's 503A list of bulk substances that pharmacies may compound. The FDA removed it from its Category 2 'do-not-compound' list in April 2026 after the nomination was withdrawn, but the agency has said that removal does not make the substance eligible for compounding. With no FDA approval and no recognized monograph, any site selling it is operating outside the prescription system.

What does 'research chemicals, not for human use' actually mean?

It functions as a liability disclaimer, not a legal pathway. A vial labeled 'for research use only' has not been reviewed for human safety, purity, or dosing, and the FDA's longstanding position is that such labeling does not make it legal to sell an unapproved drug for human consumption.

How do I tell a legitimate peptide provider from a gray-market store?

A legitimate provider requires a real clinical evaluation, prescribes only through a state-licensed pharmacy, and can tell you which pharmacy is filling your order. Gray-market signs include no prescription required, 'research only' labeling, crypto-only checkout, and no named pharmacy or prescriber.

Sources

  1. FDA — Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
  2. FDA — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2)
  3. FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
  4. FDA — Clarifies policies for compounders as national GLP-1 supply begins to stabilize
  5. FDA — Warns 30 telehealth companies against illegal marketing of compounded GLP-1s
  6. DoD Operation Supplement Safety (OPSS) — BPC-157: A Prohibited Peptide and an Unapproved Drug
  7. NABP — Buy Safely / Accredited Digital Pharmacies (safe.pharmacy)